COMMUNIQUÉS West-GlobeNewswire

Oasmia postpones the release of the Q4 and year-end report to 28 June
15/05/2019
The Board of Oasmia has decided to postpone the release of the fourth quarter and year-end 2018/2019 report from 5 June 2019 to 28 June 2019. The delay is a result of the ongoing review initiated by the new Board in [...]
Innate Pharma First Quarter 2019 Report
15/05/2019
Cash, cash equivalents and financial assets of the Company amounted to €237.1 million [*] Initiation of cohort expansion study of monalizumab and cetuximab to evaluate triple combination with an anti-PD(L)1 in patients [...]
Information financière du premier trimestre 2019
15/05/2019
Trésorerie, équivalents de trésorerie et actifs financiers s’élevant à 237,1 millions d’euros [*] Démarrage de l’extension de cohorte étudiant la triple combinaison de monalizumab et cetuximab avec un anti-PD-(L)1 chez [...]
Abeona Therapeutics traite le premier patient dans la deuxième cohorte de l'essai clinique de phase 1/2 pour ABO-101 dans le syndrome de Sanfilippo de type B (MPS IIIB)
15/05/2019
Des données intermédiaires sont attendues au second semestre 2019 NEW YORK et CLEVELAND, 15 mai 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq : ABEO), chef de file totalement intégré dans la thérapie génique [...]
Ritter Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019
15/05/2019
LOS ANGELES, May 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to [...]
Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
15/05/2019
SPINRAZA becomes the first therapy recommended in the United Kingdom for 5q spinal muscular atrophy to treat all age groups, including patients who are pre-symptomatic More than 7,500 individuals have been treated with [...]
Extendicare Announces 2019 First Quarter Results
15/05/2019
MARKHAM, Ontario, May 14, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2019. Results are presented in Canadian dollars [...]
GN Store Nord A/S successfully places EUR 330 million zero-coupon convertible bond offering consisting of Bond with Warrant Units
14/05/2019
NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ITALY, OR ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. [...]
UPDATE - NRC Health Announces Winners of the 2019 Customer and Employee Approved Awards Among Senior Living Communities
14/05/2019
Public perception of senior care is still low, but NRC Health data shows that 88% of senior living customers are happy with their care experiences LINCOLN, Neb., May 14, 2019 (GLOBE NEWSWIRE) -- NRC Health , the leading [...]
Resverlogix Announces Proposed Offering of Units
14/05/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, May 14, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced [...]
Cytori Reports Q1 2019 Business and Financial Results
14/05/2019
SAN DIEGO, May 14, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ: CYTX) (“Cytori” or the “Company”) today announced Q1 2019 financial results and provided updates on corporate activities. Q1 2019 net loss was $3. [...]
Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference
14/05/2019
SAN DIEGO, May 14, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs that address treatment resistance, announced that President and CEO Athena [...]
Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference
14/05/2019
BURLINGTON, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside [...]
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference
14/05/2019
AUSTIN, Texas, May 14, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new [...]
Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference
14/05/2019
BRIDGEWATER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief [...]
Inspire Medical Systems, Inc. Announces Publication Demonstrating Effectiveness of Inspire Therapy in Treating Obstructive Sleep Apnea in Medicare-aged Patients
14/05/2019
MINNEAPOLIS, May 14, 2019 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive [...]
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
14/05/2019
Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time GAITHERSBURG, Md., May 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today [...]
PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update
14/05/2019
BERKELEY HEIGHTS, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional [...]
Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences
14/05/2019
BOTHELL, Wash., May 14, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today [...]

Pages